Otrivine Tegen Neusverstopping (Xylometazoline Hydrochloride)

Xylometazoline hydrochloride, the active ingredient in Otrivine Tegen Neusverstopping, is an alpha‑adrenergic nasal decongestant presented as a nasal spray for topical intranasal use. It relieves nasal congestion caused by colds, sinusitis, and allergic rhinitis in adults and children.

GNH USA supplies Otrivine Tegen Neusverstopping as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Xylometazoline is a topical nasal decongestant that acts on the nasal mucosa to reduce swelling.

- Common cold: provides rapid relief of nasal blockage. - Allergic rhinitis: decreases nasal congestion associated with allergy. - Sinusitis: alleviates congestion and improves sinus drainage.

Xylometazoline may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nasal irritation or burning sensation. - Dryness of the nasal mucosa. - Sneezing. - Mild headache. - Minor nosebleeds.

Serious or Rare Side Effects: - Severe hypertension or tachycardia. - Rebound congestion (rhinitis medicamentosa) after prolonged use. - Allergic reactions including anaphylaxis. - Nasal ulceration. - Cardiac arrhythmias.

Before using Otrivine Tegen Neusverstopping, consider the following safety measures.

- Age restriction: not recommended for children under 2 years. - Duration of use: limit to 3‑5 days to avoid rebound congestion. - Cardiovascular disease: use with caution in patients with hypertension or heart disease. - Pregnancy and lactation: consult a healthcare professional before use. - Concomitant MAO inhibitors: avoid simultaneous use. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Xylometazoline can interact with other medicines, requiring attention to avoid adverse effects.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Other nasal decongestants: additive vasoconstriction may raise blood pressure. - Systemic sympathomimetics: increased cardiovascular stimulation.

Moderate Interactions (Monitor Closely):\n- Antihypertensive drugs: may reduce blood‑pressure control efficacy. - Beta‑blockers: possible additive cardiovascular effects. - Tricyclic antidepressants: monitor for increased blood pressure.